ArticleActive
Response to Comments: Intravenous Immune Globulin (IVIG) L35893
A54137
Effective: October 1, 2015
Updated: December 31, 2025
Policy Summary
This document is a response-to-comments notice indicating the draft LCD DL35893 (Intravenous Immune Globulin) has been finalized; the provided excerpt contains no specific coverage criteria, limitations, documentation, or frequency rules. For actionable coverage criteria and requirements, review the final LCD DL35893. Manual review is required to extract detailed criteria from the full policy.
Coverage Criteria Preview
Key requirements from the full policy
"No specific coverage indications are included in the provided excerpt; consult final LCD DL35893 (Intravenous Immune Globulin) for detailed indications."
Sign up to see full coverage criteria, indications, and limitations.